The safety of zoledronic acid

被引：28

作者：

Lipton, Allan ^{[1
]}

机构：

[1] Penn State Univ, Milton S Hershey Med Ctr, Hershey, PA 17033 USA

来源：

EXPERT OPINION ON DRUG SAFETY | 2007年 / 6卷 / 03期

关键词：

bisphosphonate; bone metastasis; osteonecrosis of the jaw; renal function;

D O I：

10.1517/14740338.6.3.305

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Zoledronic acid has been marketed for the past 5 years for the treatment of hypercalcemia of malignancy and malignant bone disease in patients with multiple myeloma or a broad range of solid tumors. The safety profile of zoledronic acid in this patient population is well established from the databases of several large, randomized, Phase III trials and postmarketing clinical experience. Zoledronic acid is well tolerated, with predictable side effects, primarily transient flu-like symptoms, which are manageable with standard treatment. Renal monitoring is recommended, with dose reductions for patients with renal dysfunction. Monitoring for electrolyte imbalance is also important as is calcium and vitamin D supplementation. Ocular complications are rare, and osteonecrosis of the jaw is uncommon and might be avoidable with appropriate dental care.

引用

页码：305 / 313

页数：9

共 54 条

[1] Safety and efficacy of bisphosphonates beyond 24 months in cancer patients [J].

Ali, SM ;

Esteva, FJ ;

Hortobagyi, G ;

Harvey, H ;

Seaman, J ;

Knight, R ;

Costa, L ;

Lipton, A .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (14) :3434-3437

[2] Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia Working Party [J].

Augustson, BM ;

Begum, G ;

Dunn, JA ;

Barth, NJ ;

Davies, F ;

Morgan, G ;

Behrens, J ;

Smith, A ;

Child, JA ;

Drayson, MT .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9219-9226

[3] EAU guidelines on prostate cancer [J].

Aus, G ;

Abbou, CC ;

Bolla, M ;

Heidenreich, A ;

Schmid, HP ;

van Poppel, H ;

Wolff, J ;

Zattoni, F .

EUROPEAN UROLOGY, 2005, 48 (04) :546-551

[4]

BERENSON J, 2006, MULT ASS SUPP CAR CA

[5] American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma [J].

Berenson, JR ;

Hillner, BE ;

Kyle, RA ;

Anderson, K ;

Lipton, A ;

Yee, GC ;

Biermann, JS .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3719-3736

[6] Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events [J].

Berenson, JR ;

Lichtenstein, A ;

Porter, L ;

Dimopoulos, MA ;

Bordoni, R ;

George, S ;

Lipton, A ;

Keller, A ;

Ballester, O ;

Kovacs, M ;

Blacklock, H ;

Bell, R ;

Simeone, JF ;

Reitsma, DJ ;

Heffernan, M ;

Seaman, J ;

Knight, RD .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) :593-602

[7] Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients [J].

Bertelli, G ;

Heouaine, A ;

Arena, G ;

Botto, A ;

Garrone, O ;

Colantonio, I ;

Occelli, M ;

Fea, E ;

Giubergia, S ;

Merlano, M .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (01) :46-51

[8] Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases [J].

Body, JJ ;

Diel, IJ ;

Lichinitser, MR ;

Kreuser, ED ;

Dornoff, W ;

Gorbunova, VA ;

Budde, M ;

Bergström, B .

ANNALS OF ONCOLOGY, 2003, 14 (09) :1399-1405

[9]

Chang JT, 2003, NEW ENGL J MED, V349, P1676

[10] Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases [J].

Chen, TL ;

Berenson, J ;

Vescio, R ;

Swift, R ;

Gilchick, A ;

Goodin, S ;

LoRusso, P ;

Ma, PM ;

Ravera, C ;

Deckert, F ;

Schran, H ;

Seaman, J ;

Skerjanec, A .

JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (11) :1228-1236

← 1 2 3 4 5 6 →